For Breast Cancer, Docetaxel Improves Progression-Free Survival

Share this content:
Docetaxel/capecitabine regimen for breast cancer followed by capecitabine maintenance led to longer progression-free survival.
Docetaxel/capecitabine regimen for breast cancer followed by capecitabine maintenance led to longer progression-free survival.

A docetaxel/capecitabine regimen for advanced breast cancer followed by capecitabine maintenance medication led to longer progression-free survival and response duration than a vinorelbine/capecitabine regimen, a new study published online ahead of print in the journal Cancer has shown.

For the phase III trial, researchers enrolled 100 patients with advanced metastatic breast cancer and randomly assigned 48 to receive docetaxel plus capecitabine and 42 to receive vinorelbine plus capecitabine. All patients received capecitabine maintenance medication.

Results showed that median progression-free survival was 8.4 months in the docetaxel group and 7.1 months in the vinorelbine group (HR = 1.65; 95% CI: 1.18, 2.3; P=0.0026). In addition, response duration was also longer in the docetaxel group (7.8 months vs 6.6 months; P=0.0451).

Median overall survival was 35.3 months and 19.8 months in the docetaxel and vinorelbine arms, respectively (HR = 1.48; 95% CI: 0.88, 2.47; P=0.1349).

RELATED: Increased Use of Intensive Adjuvant Chemo in Stage I Breast Cancer

Researchers found that postmenopausal women at least 40 years of age who presented with visceral metastases were more likely to benefit from the docetaxel regimen, while hormone receptor status, HER2 receptor status, or a history of taxane treatment had an impact on survival between the two treatment arms.

In regard to safety, patients in the docetaxel arm were significantly more likely to develop hand-foot syndrome compared with those in the vinorelbine arm (47% vs 16.7%; P<0.0001).

Reference

  1. Wang J, Xu B, Yuan P, et al. Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first-line treatment of patients with advanced breast cancer: phase 3 randomized trial.Cancer. 2015. [Epub ahead of print]. doi: 10.1002/cncr.29492.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters